You may have heard about a new medication that was recently FDA approved for cutaneous squamous cell carcinoma (CSCC). Libtayo (cemiplimab-rwlc) is a type of immunotherapy called a checkpoint blockade inhibitor, and it’s the first one approved to treat certain cases of CSCC. This is exciting news, so let’s break down how this new drug works and whom it might help.
Recent research suggests that there may be a link between three common medical conditions and skin cancer. We delved into the research and spoke to the experts about whether you should be concerned — or not.
Are you among the millions of people who take hydrochlorothiazide to treat high blood pressure? A recent study by researchers at the University of Southern Denmark showed a connection between this medication and squamous cell carcinoma (SCC), the second most common type of skin cancer.
Recent studies have suggested some surprising things (not beaming from the center of our solar system) that might increase your risk for skin cancer. We delved into the research to help you assess whether you should be concerned — or not.
The Skin Cancer Foundation’s Research Grants Program has given young physicians and investigators a special boost for studies that served as stepping stones to major lifesaving breakthroughs.
Each year, we award several grants to dermatology residents, fellows and young faculty to fund research and clinical studies related to skin cancer.
With the recent FDA approval of the drug nivolumab (Opdivo®, previously approved for stage IV melanoma) as a treatment for stage III melanoma, we have reached the next important phase in the immunotherapy revolution. It is a revolution that most of the world’s top experts believe will one day, very possibly within a decade, turn advanced (stages III and IV) melanoma into a chronic, or even curable, disease rather than a deadly one.
We know some of our loyal readers are medical professionals, skin cancer patients and caregivers. Many of you are as invested in skin cancer-related news and research as we are! Here’s a look back at a few 2017 headlines that got our attention.
English
Chinese (Simplified)
French
German
Italian
Portuguese
Spanish